Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...

REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...

Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $10.15. Don't Miss ...

Across the recent three months, 5 analysts have shared their insights on Regenxbio RGNX, expressing a variety of opinions ...

GET MORE AI-GENERATED SIGNALS: November 14, 2024, 18:38 pm ET, BY Tyler- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago. These figures are ...

Cash Runway Guidance: Expected to fund operations into 2026. Regenxbio Inc (NASDAQ:RGNX) is making significant progress in ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...

Regenxbio: Q3 Earnings Snapshot ...

Across the recent three months, 5 analysts have shared their insights on Regenxbio (NASDAQ:RGNX), expressing a variety of opinions spanning from bullish to bearish. The table below provides a ...

Regenxbio (RGNX) delivered earnings and revenue surprises of -0.86% and 13.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Wednesday reported a loss of $59.6 million in its third quarter. On a per-share basis, the Rockville, Maryland-based ...